An interventional study of Diuretic de/escalation based on ultrasound findings (VExUS Score) and Diuretic de/escalation based on clinical findings (CCS Score) in Cardiorenal Syndrome Type 1, sponsored by Instituto Nacional de Cardiologia Ignacio Chavez. Recruiting at 1 site in Mexico. Per ClinicalTrials.gov, last updated 2023-10-05.
Sponsored by Instituto Nacional de Cardiologia Ignacio Chavez · Not applicable, Interventional, and Treatment
A double-blind, randomized, controlled trial was conducted with the main objective of evaluating if patients with clinical assessment and VExUS reach decongestion faster within a maximum period of 7 days during the hospital stay. Likewise, the study will describe those patients who experience a decrease in serum creatinine (CrS), NT-proBNP at discharge, greater diuretic adjustment, rate of intrahospital readmission, and 30-day mortality.
76 studies on the registry are indexed under Cardio-Renal Syndrome; 22 are open to participants now.
This study's planned enrollment of 80 is above the median of 60 across 46 interventional studies indexed under Cardio-Renal Syndrome.
Browse Cardio-Renal Syndrome studies →Instituto Nacional de Cardiologia Ignacio Chavez is the lead sponsor of 45 studies on the registry; 8 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patients allocated to this will be guided (diuretic treatment) by ultrasound (VExUS) findings
Other: Diuretic de/escalation based on ultrasound findings (VExUS Score)
Patients allocated to this will be guided (diuretic treatment) by clinical congestion score (CCS) findings
Other: Diuretic de/escalation based on clinical findings (CCS Score)
Patients allocated in the experimental arm will have diuretic dosing adjusted based on ultrasound findings (VExUS Score)
Patients allocated in the experimental arm will have diuretic dosing adjusted based on clinical findings (CCS Score)
Decongestion within 7 days
Assess if the ultrasound guided arm achieves faster decongestion
Time frame: 7 days
Acutely decompensated heart failure readmission rate
Assess which strategy achieves less readmission rate
Time frame: 7 days
Length of hospital stay
Assess which strategy achieves fewer days of hospital stay
Time frame: 7 days
Total diuretic dose within 7 days
Assess which strategy has greater diuretic adjustment
Time frame: 7 days
Number of participants that initiate kidney replacement therapy
Assess which strategy is associated with kidney replacement therapy
Time frame: 30 days
Intrahospital mortality
Assess which strategy achieves less intrahospital mortality
Time frame: 30 days
Days alive out of hospital
Assess which strategy achieves more days alive out of hospital
Time frame: 1 month
Plan to share: Yes — Will share the clinical study report and results when they´re available
Supporting information: Csr
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Instituto Nacional de Cardiologia Ignacio Chavez